302 related articles for article (PubMed ID: 27147897)
1. Biomarkers and Targeted Therapy in Pancreatic Cancer.
Karandish F; Mallik S
Biomark Cancer; 2016; 8(Suppl 1):27-35. PubMed ID: 27147897
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
[TBL] [Abstract][Full Text] [Related]
3. Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer.
Karamitopoulou E
Front Oncol; 2012; 2():209. PubMed ID: 23316479
[TBL] [Abstract][Full Text] [Related]
4. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
5. Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma.
Wang Y; Wang D; Dai Y; Kong X; Zhu X; Fan Y; Wang Y; Wu H; Jin J; Yao W; Gao J; Wang K; Xu H
Front Oncol; 2021; 11():652283. PubMed ID: 34046348
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
7. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
8. FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma.
Fang R; Zhang B; Lu X; Jin X; Liu T
J Cell Biochem; 2020 Mar; 121(3):2458-2466. PubMed ID: 31692063
[TBL] [Abstract][Full Text] [Related]
9. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer.
Okazaki J; Tanahashi T; Sato Y; Miyoshi J; Nakagawa T; Kimura T; Miyamoto H; Fujino Y; Nakamura F; Takehara M; Ma B; Bando M; Kitamura S; Okamoto K; Muguruma N; Sogabe M; Takayama T
Digestion; 2020; 101(6):794-806. PubMed ID: 31563901
[TBL] [Abstract][Full Text] [Related]
11. miRNA-193b-5p Suppresses Pancreatic Cancer Cell Proliferation, Invasion, Epithelial Mesenchymal Transition, and Tumor Growth by Inhibiting eEF2K.
Gurbuz N; Kahraman N; Sonmez HE; Mokhlis HA; Kosar PA; Ozpolat B
Anticancer Agents Med Chem; 2022; 22(14):2607-2618. PubMed ID: 35718922
[TBL] [Abstract][Full Text] [Related]
12. Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer.
Pramanik KC; Makena MR; Bhowmick K; Pandey MK
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563089
[TBL] [Abstract][Full Text] [Related]
13. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic signaling pathways in pancreatic ductal adenocarcinoma.
Agrawal R; Natarajan KN
Adv Cancer Res; 2023; 159():251-283. PubMed ID: 37268398
[TBL] [Abstract][Full Text] [Related]
15. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
16. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells.
Wu YS; Chung I; Wong WF; Masamune A; Sim MS; Looi CY
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):296-306. PubMed ID: 27750041
[TBL] [Abstract][Full Text] [Related]
17. Targeted intervention of eIF4A1 inhibits EMT and metastasis of pancreatic cancer cells via c-MYC/miR-9 signaling.
Zhao Y; Wang Y; Chen W; Bai S; Peng W; Zheng M; Yang Y; Cheng B; Luan Z
Cancer Cell Int; 2021 Dec; 21(1):670. PubMed ID: 34906136
[TBL] [Abstract][Full Text] [Related]
18. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
19. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
Nimmakayala RK; Leon F; Rachagani S; Rauth S; Nallasamy P; Marimuthu S; Shailendra GK; Chhonker YS; Chugh S; Chirravuri R; Gupta R; Mallya K; Prajapati DR; Lele SM; C Caffrey T; L Grem J; Grandgenett PM; Hollingsworth MA; Murry DJ; Batra SK; Ponnusamy MP
Oncogene; 2021 Jan; 40(1):215-231. PubMed ID: 33110235
[TBL] [Abstract][Full Text] [Related]
20. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]